Therapeutic Drug Monitoring

Therapeutic drug monitoring (TDM) measures drug concentrations in biological samples to help tailor dosing, evaluate adherence, reduce toxicity, and support treatment effectiveness. It is most valuable for medicines with narrow therapeutic windows, substantial pharmacokinetic variability, complex interactions, or serious consequences from underexposure and overexposure. Clinical value depends on appropriate test selection, correctly timed sampling, validated analytical methods, and interpretation alongside patient-specific information.

TDM is moving from isolated concentration checks toward integrated medication-management workflows. Aging populations, multimorbidity, organ-function changes, polypharmacy, antimicrobial resistance, and use of biologic or highly individualized therapies are increasing the need for precise exposure assessment. At the same time, laboratories and care teams are emphasizing faster turnaround, standardized sampling protocols, interoperability with electronic health records, and clearer clinical decision support. Greater attention to stewardship and patient safety is also encouraging targeted monitoring rather than routine testing without a defined clinical question.

Artificial intelligence can strengthen TDM by combining concentration results with dosing history, renal and hepatic function, demographics, interactions, adherence signals, and pharmacokinetic models. Potential applications include identifying unusual exposure patterns, prioritizing urgent results, supporting individualized dose adjustment, and detecting inconsistencies in medication or sampling records. Reliable use requires representative training data, transparent validation, human oversight, cybersecurity, and controls against automation bias. AI should assist qualified clinicians rather than replace interpretation of context-dependent results.

North America generally benefits from established laboratory infrastructure, advanced clinical pharmacology services, and broad use of electronic records, while reimbursement and access can vary by setting. Europe emphasizes harmonized quality systems, patient safety, antimicrobial stewardship, and cross-border regulatory alignment, although implementation differs across countries. Asia-Pacific combines sophisticated urban capabilities with uneven access in rural and lower-resource areas, creating demand for scalable laboratory and digital models. Latin America is shaped by differences in laboratory capacity, procurement, and access to specialized expertise. The Middle East is developing advanced hospital services alongside varied national health-system maturity, while Africa faces infrastructure, workforce, specimen logistics, and affordability constraints that make decentralized and robust testing approaches especially important.

ASEAN countries are likely to benefit from interoperable regional practices, workforce development, and testing models suited to diverse health systems. BRICS members have opportunities to expand domestic laboratory capabilities, strengthen access to essential medicines, and coordinate research while addressing substantial differences in resources. The European Union supports common quality, data, and patient-safety principles, but national reimbursement and service delivery remain important. G7 health systems can advance evidence-based standards, digital integration, and responsible AI governance. GCC countries are positioned to develop highly connected hospital networks and centralized expertise, while NATO members may place additional emphasis on resilient supply chains, laboratory continuity, and preparedness for disrupted care environments.

Australia can focus on equitable access across geographically dispersed populations and integration with specialist services. Brazil and Mexico face priorities involving regional laboratory coverage, affordability, and consistent clinical protocols. Canada must address distance, provincial variation, and timely access for remote communities. China and India are balancing sophisticated centers with large-scale expansion of standardized testing and clinical expertise. France, Germany, Italy, and Spain can continue refining reimbursement, interoperability, and stewardship-linked use within established health systems. Japan and South Korea have strong technology and hospital capabilities, with continued attention to aging populations and workflow integration. Russia’s priorities include laboratory resilience, access to specialized expertise, and continuity across a geographically extensive system. The United Kingdom can emphasize coordinated pathways, quality assurance, and data-enabled prescribing. The United States can focus on consistent interpretation, payer and site-of-care variation, and integration across laboratories, hospitals, and outpatient care.

Industry leaders should define TDM around specific clinical decisions, standardize patient preparation and sampling times, and use quality indicators that track analytical performance, turnaround, interpretive accuracy, and clinical follow-through. Investment should favor interoperable laboratory information systems, pharmacist and clinical pharmacology expertise, and validated pharmacokinetic decision support. Organizations should establish governance for AI that includes prospective validation, bias monitoring, audit trails, privacy safeguards, and clear escalation to clinicians. Regional strategies should pair centralized expertise with decentralized collection or testing where appropriate, supported by training, dependable supply chains, and equitable access policies.

This executive summary uses a structured qualitative assessment of therapeutic drug monitoring, focusing on clinical applications, workflow requirements, technology, regulation, health-system capacity, and geographic variation. Insights are derived from established principles of pharmacokinetics, laboratory medicine, medication safety, antimicrobial stewardship, digital health, and responsible AI. Regional, group, and country observations are framed as contextual priorities rather than quantitative market claims. No market estimates, market shares, forecasts, or company-specific comparisons are used.

Therapeutic drug monitoring is most effective when accurate measurement is connected to timely clinical action. The field is being shaped by individualized therapy, medication safety, antimicrobial stewardship, digital interoperability, and AI-assisted interpretation, but benefits will depend on validated methods and capable professionals. Leaders that combine standardized processes, resilient laboratory access, responsible data use, and equitable implementation can improve the practical contribution of TDM across diverse care environments.